Apoptosis and immunophenotyping of peripheral blood lymphocytes in Iranian COVID‐19 patients: Clinical and laboratory characteristics

Saeid Taghiloo,Masoud Aliyali,Siavash Abedi,Hossein Mehravaran,Ali Sharifpour,Ehsan Zaboli,Mohammad Eslami‐Jouybari,Roya Ghasemian,Laleh Vahedi‐Larijani,Hadi Hossein‐Nattaj,Omolbanin Amjadi,Hadiseh Rezazadeh,Abolghasem Ajami,Hossein Asgarian‐Omran
DOI: https://doi.org/10.1002/jmv.26505
IF: 20.693
2020-09-28
Journal of Medical Virology
Abstract:<p>A novel member of human coronavirus, named SARS‐CoV‐2, has been recently recognized in China and rapidly spread worldwide. Studies showed the decreasing of peripheral blood lymphocytes in a majority of patients. In this study, we have reported the clinical features, laboratory characteristics, the frequency of peripheral blood lymphocyte subpopulations and their apoptosis pattern in Iranian COVID‐19 patients. Demographic and clinical data of 61 hospitalized confirmed cases with COVID‐19 at Imam Khomeini Hospital were collected and analyzed. Peripheral blood mononuclear cells were isolated from all samples and the apoptosis pattern was evaluated using Annexin V/propidium iodide method. The frequency of lymphocyte subsets including T‐CD4<sup>+</sup>, T‐CD8<sup>+</sup>, NK, B cells, and monocytes was measured in all patients and 31 controls by flow cytometry. Our findings demonstrated that the percentage of lymphocytes, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells were decreased in COVID‐19 patients compared to control group. Regarding the clinical severity, the number of lymphocytes, CD4<sup>+</sup>, CD8<sup>+</sup> T cells, and NK cells were also decreased in severe cases when compared to mild cases. Finally, our data have also indicated the increasing in apoptosis of mononuclear cells from COVID‐19 patients which was more remarkable in severe clinical cases. The frequency of immune cells is a useful indicator for prediction of severity and prognosis of COVID‐19 patients. These results could help to explain the immunopathogenesis of SARS‐CoV‐2 and introducing of novel biomarkers, therapeutic strategies, and vaccine candidates.</p><p>This article is protected by copyright. All rights reserved.</p>
virology
What problem does this paper attempt to address?